Trial Search Results

Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis Using PET/CT

The investigators wish to evaluate the feasibility of [18F]FP-R01-MG-F2 PET/CT scanning in patients with Idiopathic Pulmonary Fibrosis.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Pliant Therapeutics, Inc.


  • Drug: [18F]FP-R01-MG-F2


Early Phase 1


Inclusion Criteria:

   - Patient is >/= 60 years old

   - Patient provides written informed consent

   - Patient diagnosed with IPF by a pulmonologist according to ATS guidelines

   - Patient has high-resolution CT with definite Usual Interstitial Pneumonia (UIP)

   - Patient has PFT's within the last 12 months with:

      - FVC<85% predicted

      - DLCO<65% predicted

   - FEV1/FCV ratio >70

   - Patient is able to comply with study procedures

      - Scanning Option A (60 +20 +20 mins) OR

      - Scanning Option B (10 +10 mins)

Exclusion Criteria:

   - Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   - Patient has a history of any clinically significant lung disease other than IPF as
   determined by pulmonologist

   - Patient has had a lung infection of any kind in the last 3 months

Ages Eligible for Study

60 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrea Otte